Fig. 3 | Acta Pharmacologica Sinica

Fig. 3

From: Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors

Fig. 3

Compound 2 blocked cell cycle progression at G1 phase in TMD8 cells. a TMD8 cells were treated with indicated concentrations of 2, ibrutinib and ACP-196 for 48 h. b The percentage of the G1 phase cells was quantitatively depicted. Statistically significant differences were presented as *P < 0.05, **P < 0.01, compared with the control group. c TMD8 cells were treated with 2, ibrutinib and ACP-196 for 48 h, and the total cell lysates were analyzed by Western blot to evaluate the alterations of G1 phase related protein

Back to article page